文献速递肿瘤 PET/CT核素与放射性配体治疗

177Lu-PSMA-617联合NOX66治疗转移性去势抵抗性前列腺癌的I/II期试验中治疗后68Ga-PSMA-11 PET/CT与18F-FDG PET/CT的预后价值

The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
PubMed 文献 · J Nucl Med · 2022-06-23

LuPIN子研究纳入56例进展性转移性去势抵抗性前列腺癌男性,接受最多6剂177Lu-PSMA-617和放射增敏剂NOX66,在入组和出组时行68Ga-PSMA-11和18F-FDG PET/CT。分析37例完成前后分子影像者,PSMA TTV增加≥30%与更差OS相关(中位10.2 vs 23.6个月,P=0.002),多因素分析仅PSMA TTV增加和PSA进展为OS独立预后因素。

要点

  • PSMA TTV增加≥30%与更差OS相关(中位10.2 vs 23.6个月,P=0.002)。
  • 多因素分析仅PSMA TTV增加和PSA进展为OS独立预后因素。
  • 18F-FDG TTV增加>30%与更短PSA PFS相关(中位3.5 vs 8.6个月,P<0.001)。

核心结论

  • 定量PSMA TTV变化在177Lu-PSMA-617治疗中具有作为预后生物标志物的强大潜力,且独立于18F-FDG PET参数、PSA或影像学进展。
  • 作者认为有必要进一步研究治疗后PET作为影像生物标志物的价值。

研究设计与样本

  • LuPIN试验子研究,56例进展性转移性去势抵抗性前列腺癌男性入组,接受最多6剂177Lu-PSMA-617和放射增敏剂NOX66。
  • 在入组和出组时行68Ga-PSMA-11和18F-FDG PET/CT、诊断CT和骨扫描。
  • 定量分析追踪总肿瘤体积(TTV)和SUV变化,采用单因素和多因素分析检验TTV变化(连续和>30%)、SUVmax、PSA和影像学进展与PSA PFS和OS的关联。

主要发现

  • 分析37/56例同时完成筛查和治疗后分子影像者,70%(26/37)PSA缓解超过50%,中位PSA PFS为8.6个月,中位OS为22个月。
  • 治疗反应中,95%(35/37)PSMA SUVmax降低,68%(25/37)PSMA TTV降低;18F-FDG SUVmax在51%(18/35)降低,18F-FDG TTV在67%(22/35)降低。
  • PSMA TTV增加至少30%与更差OS相关(中位10.2 vs 23.6个月;P=0.002);PSMA SUVmax变化与PSA PFS或OS无关。
  • 18F-FDG SUVmax升高与更差OS相关(中位20.7 vs 25.7个月;P<0.01);18F-FDG TTV增加>30%与更短PSA PFS相关(中位3.5 vs 8.6个月;P<0.001)但与OS无关。
  • PSA进展和影像学进展均与更短OS相关(中位14.5 vs 25.7个月[P<0.001]和12.2 vs 23.6个月[P=0.002]);多因素分析仅PSMA TTV增加和PSA进展为OS独立预后因素(风险比分别为5.1[95%CI 1.5-17.1;P=0.008]和3.5[95%CI 1.1-10.9;P=0.03])。

关键数值与推荐

  • PSMA TTV增加≥30%与更差OS相关(中位10.2 vs 23.6个月;P=0.002)。
  • 18F-FDG SUVmax升高与更差OS相关(中位20.7 vs 25.7个月;P<0.01)。
  • 18F-FDG TTV增加>30%与更短PSA PFS相关(中位3.5 vs 8.6个月;P<0.001)。
  • 多因素分析中PSMA TTV增加和PSA进展为OS独立预后因素(风险比5.1[95%CI 1.5-17.1;P=0.008]和3.5[95%CI 1.1-10.9;P=0.03])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出有必要进一步研究治疗后PET作为影像生物标志物的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-PSMA-617 therapy has shown high prostate-specific antigen (PSA) response rates in men with metastatic castration-resistant prostate cancer. However, early treatment resistance is common. This LuPIN substudy aimed to determine the prognostic value of posttreatment quantitative PET for PSA progression-free survival (PFS) and overall survival (OS) with 177Lu-PSMA-617 therapy. Methods: Fifty-six men with progressive metastatic castration-resistant prostate cancer were enrolled in the LuPIN trial and received up to 6 doses of 177Lu-PSMA-617 and a radiation sensitizer (NOX66). 68Ga-PSMA-11 and 18F-FDG PET/CT, diagnostic CT, and bone scanning were performed at study entry and exit. Quantitative analysis tracked change in total tumor volume (TTV) and SUV. Univariable and multivariable analyses were conducted to examine the association of change in TTV (continuous and >30%), SUVmax, PSA, and radiographic progression with PSA PFS and OS. Results: All men (37/56) who underwent both screening and posttreatment molecular imaging were analyzed; 70% (26/37) had a PSA response of more than 50%. Median PSA PFS was 8.6 mo, and median OS was 22 mo. Clinical progression had occurred at trial exit in 54% (20/37). In response to treatment, a reduced PSMA SUVmax was demonstrated in 95% (35/37) and a reduced PSMA TTV in 68% (25/37). An increase in PSMA TTV by at least 30% was associated with worse OS (median, 10.2 vs. 23.6 mo; P = 0.002). Change in PSMA SUVmax was not associated with PSA PFS or OS. 18F-FDG SUVmax was reduced in 51% (18/35) and 18F-FDG TTV in 67% (22/35). An increased 18F-FDG SUVmax was associated with worse OS (median, 20.7 vs. 25.7 mo; P < 0.01). An 18F-FDG TTV increase by more than 30% was associated with a short PSA PFS (median, 3.5 vs. 8.6 mo; P < 0.001) but not OS. Both PSA and radiographic progression were associated with shorter OS (median, 14.5 vs. 25.7 mo [P < 0.001] and 12.2 vs. 23.6 mo [P = 0.002]). On multivariable analysis, only increased PSMA TTV and PSA progression remained independently prognostic of OS (hazard ratio, 5.1 [95% CI, 1.5-17.1; P = 0.008] and 3.5 [95% CI, 1.1-10.9; P = 0.03], respectively). Conclusion: Change in quantitative PSMA TTV has strong potential as a prognostic biomarker with 177Lu-PSMA-617 therapy, independent of 18F-FDG PET parameters, PSA, or radiographic progression. Further research into the value of posttreatment PET as an imaging biomarker is warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pathmanandavel S, Crumbaker M, Nguyen A, et al. The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). J Nucl Med. 2022. PMID: 35738906. doi:10.2967/jnumed.122.264104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。